Angela A. Armstrong

Array ( [id] => 10978455 [patent_doc_number] => 20160175398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Chimeric Immunoreceptor Useful in Treating Human Cancers' [patent_app_type] => utility [patent_app_number] => 14/976689 [patent_app_country] => US [patent_app_date] => 2015-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 13489 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14976689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12091133 [patent_doc_number] => 20170348225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'LIQUID PHARMACEUTICAL COMPOSITION' [patent_app_type] => utility [patent_app_number] => 15/536941 [patent_app_country] => US [patent_app_date] => 2015-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26536 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699863 [patent_doc_number] => 20170360886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => METHODS FOR TREATING AND PREVENTING CARDIOMYOPATHY [patent_app_type] => utility [patent_app_number] => 15/528012 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15528012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11003865 [patent_doc_number] => 20160200813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'LRP-8 Binding Proteins' [patent_app_type] => utility [patent_app_number] => 14/967260 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 47699 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14967260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14388445 [patent_doc_number] => 10307480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Anti-pro/latent-myostatin antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/524651 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 52 [patent_no_of_words] => 31872 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074241 [patent_doc_number] => 20160271205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'USE OF ANGIOTENSIN II (AII) RECEPTOR AGONISTS TO PREVENT OR REDUCE HEMODIALYSIS-ASSOCIATED SKELETAL MUSCLE CRAMPS' [patent_app_type] => utility [patent_app_number] => 14/933862 [patent_app_country] => US [patent_app_date] => 2015-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2637 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14933862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12060076 [patent_doc_number] => 20170336420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES' [patent_app_type] => utility [patent_app_number] => 15/524054 [patent_app_country] => US [patent_app_date] => 2015-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13290 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714181 [patent_doc_number] => 20160060328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'COMPOSITIONS AND METHODS FOR BINDING CYSTEINYL LEUKOTRIENES (CYSLTS) FOR TREATMENT OF DISEASE' [patent_app_type] => utility [patent_app_number] => 14/803637 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 35760 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14803637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936481 [patent_doc_number] => 20170240632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'COMPOSITIONS AND METHODS FOR IDENTIFYING AND TREATING CACHEXIA OR PRE-CACHEXIA' [patent_app_type] => utility [patent_app_number] => 15/519212 [patent_app_country] => US [patent_app_date] => 2015-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 27586 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15519212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15068501 [patent_doc_number] => 10463716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone [patent_app_type] => utility [patent_app_number] => 15/519021 [patent_app_country] => US [patent_app_date] => 2015-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 50 [patent_no_of_words] => 26459 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15519021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988910 [patent_doc_number] => 20160185855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'ANTI-LRP5 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/879702 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 22451 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14879702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647897 [patent_doc_number] => 20170143799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'Methods and Compositions for Treatment of Conditions Associated with Elevated Triglycerides' [patent_app_type] => utility [patent_app_number] => 15/318937 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14551 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15318937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000188 [patent_doc_number] => 20170304343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/516115 [patent_app_country] => US [patent_app_date] => 2015-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 54998 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10745349 [patent_doc_number] => 20160091499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'CARDIOVASCULAR RISK EVENT PREDICTION AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/865853 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 38626 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14865853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943297 [patent_doc_number] => 20170247448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'HUMANIZED ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/511596 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 43552 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 27 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706852 [patent_doc_number] => 20160053000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'APELIN ANTIGEN-BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/839662 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18480 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14839662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129289 [patent_doc_number] => 20160326263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'NME Inhibitors and Methods of Using NME Inhibitors' [patent_app_type] => utility [patent_app_number] => 14/831825 [patent_app_country] => US [patent_app_date] => 2015-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 29823 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14831825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10708187 [patent_doc_number] => 20160054334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'FUTURE CARDIAC EVENT BIOMARKERS' [patent_app_type] => utility [patent_app_number] => 14/830373 [patent_app_country] => US [patent_app_date] => 2015-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 19513 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14830373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13918459 [patent_doc_number] => 10203341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => Neprilysin as heart failure prognostic marker [patent_app_type] => utility [patent_app_number] => 15/506665 [patent_app_country] => US [patent_app_date] => 2015-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5887 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15506665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10450696 [patent_doc_number] => 20150335710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'OXIDIZED LDL INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/820259 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8419 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820259 [rel_patent_id] =>[rel_patent_doc_number] =>)